

Research article

Open Access

Nasal carriage of a single clone of community-acquired methicillin-resistant *Staphylococcus aureus* among kindergarten attendees in northern Taiwan

Wen-Tsung Lo^{1,2}, Wei-Jen Lin¹, Min-Hua Tseng¹, Jang-Jih Lu³, Shih-Yi Lee³, Mong-Ling Chu¹ and Chih-Chien Wang*¹

Address: ¹Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan., ²Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan. and ³Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

Email: Wen-Tsung Lo - drluoped@yahoo.com.tw; Wei-Jen Lin - ndmcmdped@yahoo.com.tw; Min-Hua Tseng - doc31089@yahoo.com.tw; Jang-Jih Lu - jjl@ndmctsg.edu.tw; Shih-Yi Lee - ecm318@ndmctsg.edu.tw; Mong-Ling Chu - mlchu@yahoo.com.tw; Chih-Chien Wang* - ndmcccw@yahoo.com.tw

* Corresponding author

Published: 1 June 2007

Received: 15 January 2007

BMC Infectious Diseases 2007, **7**:51 doi:10.1186/1471-2334-7-51

Accepted: 1 June 2007

This article is available from: <http://www.biomedcentral.com/1471-2334/7/51>

© 2007 Lo et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: To evaluate the prevalence and microbiological characterization of community-acquired (CA) methicillin-resistant *Staphylococcus aureus* (MRSA) nasal carriage in a kindergarten.

Methods: Point prevalence study. Nasal swabs were collected from healthy children younger than 7 years of age who were attending a kindergarten in Taipei, Taiwan. A parent questionnaire regarding MRSA risk factors was administered simultaneously. All CA-MRSA colonization isolates were archived for subsequent antimicrobial susceptibility and molecular typing.

Results: Of the 68 children who participated in the study, 17 (25%) had *S. aureus* isolated from nasal swabs. Nine (13.2%) of the 68 children had CA-MRSA carriage, and none of them had any identified risk factors. Antimicrobial susceptibility testing revealed all of the 9 CA-MRSA colonization isolates had uniformly high resistance (100%) to both clindamycin and erythromycin, the macrolide-lincosamide-streptogramin-constitutive phenotype and the *ermB* gene. Pulsed-field gel electrophoresis revealed 8 (88.9%) of 9 CA-MRSA colonization isolates were genetically related and multilocus sequence typing revealed all isolates had sequence type 59. All of the colonization isolates carried the staphylococcal cassette chromosome *mec* type IV, but none were positive for the Panton-Valentine leukocidin genes.

Conclusion: The results of this study suggest that a single predominant CA-MRSA colonization strain featuring high clindamycin resistance circulated in this kindergarten. Additionally, due to the established transmissibility of colonization isolates, the high prevalence of nasal carriage of CA-MRSA among healthy attendees in kindergartens may indicate the accelerated spread of CA-MRSA in the community.

Background

Beginning in the late 1990s, studies from various cities in the United States and other countries reported a significant prevalence of community-acquired (CA) methicillin-resistant *Staphylococcus aureus* (MRSA) colonization or infection among both children and adults [1-6], and especially the presence of increasing numbers of patients with CA-MRSA who do not appear to demonstrate evident risk factors [2,4-6]. Reports of pediatric deaths as a consequence of CA-MRSA infections further illustrated the potential seriousness of this emergence [1].

Recently, the results of our epidemiological investigation relating to CA-MRSA infections among healthy children in Taiwan have also been a cause for concern because they indirectly reflect that there might be a reservoir of children with asymptomatic CA-MRSA colonization in the community [7]. Because of the geographic diversity in the prevalence of MRSA carriage and the possible transmission from any individual colonized with MRSA [8], measurement of the rate of CA-MRSA carriage may be helpful to estimate the potential for spread of CA-MRSA in the community. Therefore, this preliminary study was conducted to determine the prevalence of CA-MRSA colonization of the anterior nares among healthy attendees of a kindergarten. In addition to characterizing these CA-MRSA colonization isolates, we also compared them with healthcare-associated MRSA (HA-MRSA) isolates via molecular analyses.

Methods

Study subjects

This was a point prevalence study conducted in a kindergarten in northern Taiwan. The study proposal was reviewed and approved by the National Defense Medical Center Institutional Review Board. Participant or parental informed consent was obtained in all cases. The kindergarten was a for-profit facility that the director had owned and operated for 28 years. Attendees were divided into the following four classes by age: toddler (2-younger than 4 years), older toddler (4-younger than 5 years), preschool child (5-younger than 6 years), and child attending the kindergarten prior to leaving for school (6-younger than 7 years). All classes shared a room for an average of one-half hour in the morning and indoor play areas.

All kindergarten attendees younger than 7 years of age, regardless of their medical history, were considered eligible to participate in this study. Participants and their guardians were approached by the same investigative team throughout the study period.

Cultures and questionnaires

After obtaining written consent, study personnel verbally administered a questionnaire to the guardians to collect

demographic data and information on risk factors of all children and their household contacts. Risk factors for MRSA infection analyzed in this study included the following: (1) hospitalization, surgery, endotracheal intubation or antimicrobial therapy in the previous 12 months, (2) underlying chronic disorder (e.g., asthma, chronic lung disease, atopic dermatitis, heart disease or neurological disease) (3) presence of an indwelling venous or urinary catheter, or (4) household contact with an individual with an identified risk factor, (e.g., long-term care facility residence, intravenous drug abuse, recurrent skin infections, history of MRSA infection or colonization) or a worker in a health care environment in the 12 months preceding the culture [9].

A specimen for culture was obtained from both anterior nares of each enrolled child with a sterile dry cotton swab, pre-moistened with sterile water. The swab was immediately inoculated onto 5% sheep blood agar which was then incubated for 36 to 48 hours at 35°C.

Bacterial strains and antimicrobial susceptibility testing

Staphylococci were identified based on colonial morphology, catalase testing, tube-coagulase testing, DNase reaction, mannitol fermentation, tellurite reduction, and an oxidation-fermentation test. MRSA identification and antimicrobial susceptibility were determined according to the Clinical Laboratory Standards Institute (formerly known as the National Committee for Clinical Laboratory Standards) guidelines [10,11]. In vitro macrolide-lincosamide-streptogramin-inducible (MLS_S) phenotypes were detected by the double-disk diffusion assay [12]. During the study period, all children colonized with CA-MRSA isolates were compared with consecutive control subjects with HA-MRSA infection. Susceptibility to penicillin-G, oxacillin, clindamycin, erythromycin, gentamicin, vancomycin, tetracycline, ciprofloxacin and trimethoprim/sulfamethoxazole was determined using the disc-diffusion method [10,11].

Multilocus sequence typing (MLST)

MLST was performed by polymerase chain reaction (PCR) amplification and sequencing of seven housekeeping genes using primers designed by Enright et al [13]. Each sequence was submitted to the MLST database website for assignment of the allelic profile and sequence type (ST).

Pulsed-field gel electrophoresis (PFGE)

All *S. aureus* nasal-colonization isolates were analyzed for epidemiologic relatedness by PFGE of chromosomal DNA performed using the enzyme *Sma*I (New England Biolabs, Beverly, Mass, USA). DNA was separated in 0.9% agarose gels at 14°C in 0.5× TBE buffer with a CHEF Mapper XA system (Bio-Rad Laboratories, Hercules, CA, USA) for 31.5 h, with initial and final switching times of 2 and 30

s, respectively. Gels were stained with ethidium bromide and photographed under UV illumination. The derived patterns were analyzed using GelCompar software (Applied Maths, Kortrijk, Belgium). Results were analyzed using the unweighted pair group method for arithmetic averages (UPGMA) and the Dice coefficient with 1.2% band tolerance [14]. The strain types were designated in alphabetical order, and a new type, if identified, was designated consecutively. MRSA isolates sharing closely related PFGE profiles from one existing strain type were defined as its subtypes and labeled with suffixes of Arabic numbers.

Staphylococcal cassette chromosome mec (SCCmec) typing

SCCmec typing was performed by means of PCR using sets of region-specific primers as described elsewhere [15,16].

PCR amplification of mecA, lukS-PV, lukF-PV, ermA, ermB, ermC and msrA

PCR for *mecA* was performed using relevant published sequences and temperature parameters [17]. The PCR amplification of the *lukS-PV*, *lukF-PV*, and genes encoding Panton-Valentine leukocidin (PVL) components was performed as described elsewhere [18]. The presence of MLS resistance genes (*ermA*, *ermB*, *ermC* and *msrA*) was determined according to previously described methods [19,20].

Statistical analysis

Data collection and analyses were performed with the Fisher's exact test using SPSS software, version 10.0 (Statistical Package for Social Sciences; SPSS for Windows, Inc., Chicago, IL, USA). A *P* value of < 0.05 was considered to represent a statistically significant difference between tested groups.

Results

Prevalence of S. aureus and CA-MRSA nasal carriage

Sixty-eight children with ages ranging from 2.7 years to 6.9 years were enrolled in the study. The median age of the

children was 5.5 years, and there was an equal number of boys and girls. Nasal screening identified 17 (25%) *S. aureus* carriers including 8 (11.8%) CA methicillin-sensitive *S. aureus* (MSSA) carriers and 9 (13.2%) CA-MRSA carriers. Of the 9 children colonized with CA-MRSA (median age, 5.7 years), none exhibited any identified risk factor.

Antibiotic susceptibility profiles of CA-MRSA colonization isolates

Antimicrobial susceptibility testing of the 9 CA-MRSA colonization isolates showed the following susceptibility rates: vancomycin (100%), gentamicin (88.9%), tetracycline (100%), clindamycin (0%), erythromycin (0%), trimethoprim/sulfamethoxazole (100%) and ciprofloxacin (100%). For CA-MSSA and CA-MRSA colonization isolates, the rates of resistance to erythromycin (50% and 100%, respectively) and clindamycin (0% and 100%, respectively) were significantly different. Moreover, the CA-MRSA isolates from children in the colonization-group were more likely to be susceptible to gentamicin, tetracycline, trimethoprim/sulfamethoxazole, and ciprofloxacin than the HA-MRSA isolates (Table 1). No significant differences were found between the 2 groups with respect to susceptibilities to either clindamycin or erythromycin.

Of the 9 CA-MRSA colonization isolates tested using the double-disk diffusion method and PCR for detection of macrolide resistance genes, all had the MLS-constitutive (MLSc) phenotype and *ermB* gene.

Molecular characterization of CA-MRSA colonization isolates

All of the 9 CA-MRSA colonization isolates tested positive for the *mecA* gene and had the ST59 genetic background. The 17 *S. aureus* isolates collected for PFGE typing were categorized into 7 distinct PFGE patterns (Figure 1). The pulsotypes of all 9 CA-MRSA colonization isolates tested differed from those of the 8 MSSA colonization isolates. In addition, based on the interpretable phylogenetic tree,

Table 1: Antibiotic susceptibility of MRSA isolates from the kindergarten and hospitalized patients

Antibiotic	% of Resistant		95% CI*	P-value
	Kindergarten Colonizers (N = 9)	Clinical Hospital Strains (N = 10)		
Penicillin	100	100	NA/NM	NA/NM
Clindamycin	100	100	NA/NM	NA/NM
Erythromycin	100	100	NA/NM	NA/NM
Gentamicin	11.1	100	57.82–119.98	0.001
Vancomycin	0	0	NA/NM	NA/NM
Tetracycline	0	90	60.85–119.15	0.001
Trimethoprim/sulfamethoxazole	0	90	60.85–119.15	0.001
Ciprofloxacin	0	100	89.44–110.56	<0.001

*NA, not applicable; NM, not measured.

1 set of CA-MRSA colonization isolates (type A, A₁, A₂ and A₃) (8/9; 88.9%) appeared to be clustered, with homology percentages of >80%, while the other isolate from 1 colonized child was a distinct strain, type B. Two subjects with CA-MRSA were a sibling pair and their isolates belonged to strain type A. The 2 children colonized with strain type A₁ were unrelated. Moreover, in addition to the 9 CA-MRSA colonization isolates, HA-MRSA isolates from clinical specimens collected from our hospitalized patients and matched by the geographical area and study period were also included in the PFGE analysis. The *Sma*I genomic fingerprints of the HA-MRSA isolates from these corresponding hospitalized patients were found to be totally different from those of the CA-MRSA nasal-colonization isolates (data not shown).

The results of SCCmec typing demonstrated that SCCmec type IV (100%) was the most-common type, nevertheless, staphylococcal toxin genes *lukS-PV* and *lukF-PV* were not present in any of the 9 CA-MRSA colonization isolates.

Discussion

The *S. aureus* prevalence among children participating in this study was 25%, a value consistent with historical rates of *S. aureus* colonization [21]. Although various reports have suggested that the carriage of MRSA by persons without health care-associated risks has increased, significant heterogeneity among the study population existed [22]. The rate of CA-MRSA carriage of 13.2% in this study is within the reported range for children [23-25]. However, a recent study by Alfaro et al [26] found the highest reported rate (22%) of MRSA carriage in a group of South Texas children. This rate, which was higher than in the present study, was also found in one of the first known

areas to experience the emergence and epidemic of CA-MRSA infections in children.

Review of antimicrobial susceptibility patterns in this study demonstrated that both clindamycin and erythromycin resistance were extraordinarily high among our CA-MRSA colonization isolates, which is in contrast with previous studies of CA-MRSA isolates from hospitalized children or adults, and colonized children [4,27,28]. Based on erythromycin resistance, *S. aureus* can be divided into 2 distinct phenotypes expressed either constitutively or inducibly [19]. In this study, the MLS_C phenotype was more prevalent than MLS_S phenotype in CA-MRSA colonization isolates, which is in agreement with previous studies [19,29,30]. In 2002, Almer et al [19] and also other investigators [29,31] reported *ermA* was the dominant *erm* gene present in their MRSA isolates and that the prevalence of *ermB* in *S. aureus* was less than 2%. Recently, SCCmec types II and III in HA-MRSA isolates were shown to contain *ermA* gene on a transposon (Tn554), which is responsible for inducible MLS resistance [32-34]. Moreover, in USA300 (ST8) CA-MRSA strains, constitutive MLS resistance was mediated by *ermC* gene that is typically located on a plasmid (pUSA03) [35,36]. In the present study, however, *ermB* was more widespread than *ermA* or *ermC* among CA-MRSA colonization isolates, which is in agreement with our recent findings in CA-MRSA isolates causing skin and soft-tissue infections [7]. In Taiwan, the widespread use of antimicrobials in the community may elicit some level of selective pressure which may account for the remarkably high incidence of clindamycin and erythromycin resistance among CA-MRSA isolates from colonized children [37,38].

In Europe, PVL genes have been associated with *S. aureus* isolates deriving from community-associated staphylococcal skin infections and also necrotizing pneumonia [18,39]. Recent evidence revealed that, although they do not share a common genetic lineage, PVL genes and the SCCmec IV allele are more prevalent among CA-MRSA strains from 3 different continents than among HA-MRSA strains globally [40]. In our colonized CA-MRSA isolates, SCCmec IV was indeed common, however, PVL genes were not found in any of these isolates. Since this observation is somewhat limited by the small number of isolates analyzed, persistent sampling from different parts of Taiwan and further molecular studies of such isolates are required to clarify this phenomenon. Although all 9 CA-MRSA colonization isolates were ST59, comparisons of PFGE patterns in this study indicated that 8 (88.9%) of the 9 isolates from this kindergarten were of a single clonal origin. The eight patterns were not indistinguishable by PFGE, but differed by 1 to 2 bands. Analysis of the results of this study suggest that 1 predominant CA-MRSA strain was circulating in the studied kindergarten and may




Figure 1
Schematic representation of PFGE pulsotypes of 17 study isolates (lanes 1–17) together with a dendrogram showing percent similarities of patterns.

be colonizing individuals not previously believed to be at risk.

Conclusion

Our data suggest that the clonal spread of CA-MRSA was principally responsible for the high MRSA burden in this kindergarten. Of particular interest and importance is the future impact to the community or, indeed, elsewhere, should this common clone of CA-MRSA become more prevalent in Taiwan. Accordingly, much larger epidemiological studies pertaining to MRSA in the community are warranted to determine the scope of this emerging problem.

Abbreviations used

CA-MRSA, community-acquired methicillin-resistant *Staphylococcus aureus*; HA-MRSA, healthcare-associated methicillin-resistant *Staphylococcus aureus*; MLS, macrolide-lincosamide-streptogramin; PFGE, pulsed-field gel electrophoresis; SCCmec, staphylococcal cassette chromosome mec; PCR, polymerase chain reaction; PVL, Panton-Valentine leukocidin; MSSA, methicillin-sensitive *S. aureus*.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

WTL conceived the study and designed it together with CCW. WTL conducted the experiments with contribution from WJL, MHT, JYL, SYL, MLC, and CCW. WTL, WJL, and MHT collected isolates. WTL drafted the article with contribution from JYL, MLC, and CCW.

Acknowledgements

We are grateful to Robert S. Daum at the University of Chicago (Chicago, IL) and L. K. Siu at the National Health Research Institute (Taipei, Taiwan) for the laboratory support. We thank Mrs. Shu-Ying Tsai for her technical assistance with this project. This work was supported by a grant from Tri-Service General Hospital (grant TSGH-C94-12).

References

- Centers for Disease Control and Prevention: **Four pediatric deaths from community-acquired methicillin-resistant *Staphylococcus aureus*: Minnesota and North Dakota, 1997-1999.** *JAMA* 1999, **282**:1123-1125.
- Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS: **Community-acquired methicillin-resistant *Staphylococcus aureus* in children with no identified predisposing risk.** *JAMA* 1998, **279**:593-598.
- Adcock PM, Pastor P, Medley F, Patterson JE, Murphy TV: **Methicillin-resistant *Staphylococcus aureus* in two child care centers.** *J Infect Dis* 1998, **178**:577-580.
- Gorak EJ, Yamada SM, Brown JD: **Community-acquired methicillin-resistant *Staphylococcus aureus* in hospitalized adults and children without known risk factors.** *Clin Infect Dis* 1999, **29**:797-800.
- Warshawsky B, Hussain Z, Gregson DB, Alder R, Austin M, Bruckschwaiger D, Chagla AH, Daley J, Duhaime C, McGhie K, Pollett G, Potters H, Schiedel L: **Hospital- and community-based surveil-**

lance of methicillin-resistant *Staphylococcus aureus*: previous hospitalization is the major risk factor. *Infect Control Hosp Epidemiol* 2000, **21**:724-727.

- Nakamura MM, Rohling KL, Shashaty M, Lu H, Tang YW, Edwards KM: **Prevalence of methicillin-resistant *Staphylococcus aureus* nasal carriage in the community pediatric population.** *Pediatr Infect Dis J* 2002, **21**:917-921.
- Wang CC, Lo WT, Chu ML, Siu LK: **Epidemiological typing of community-acquired methicillin-resistant *Staphylococcus aureus* isolates from children in Taiwan.** *Clin Infect Dis* 2004, **39**:481-487.
- Pan ES, Diep BA, Charlebois ED, Auerswald C, Carleton HA, Sensabaugh GF, Perdreau-Remington F: **Population dynamics of nasal strains of methicillin-resistant *Staphylococcus aureus* - and their relation to community-associated disease activity.** *J Infect Dis* 2005, **192**:811-818.
- Hussain FM, Boyle-Vavra S, Bethel CD, Daum RS: **Current trends in community-acquired methicillin-resistant *Staphylococcus aureus* at a tertiary care pediatric facility.** *Pediatr Infect Dis J* 2000, **19**:1163-1166.
- National Committee for Clinical Laboratory Standards: **Methods for disk diffusion: approved standard M2-A8: performance standards for antimicrobial disk susceptibility tests.** Wayne (PA): The Committee; 2003.
- National Committee for Clinical Laboratory Standards: **Performance standards for antimicrobial susceptibility testing: 14th informational supplement. NCCLS document M100-S14.** Wayne (PA): The Committee; 2004.
- Weisblum D, Demohn V: **Erythromycin-inducible resistance in *Staphylococcus aureus*: survey of antibiotic classes involved.** *J Bacteriol* 1969, **98**:447-452.
- Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG: **Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*.** *J Clin Microbiol* 2000, **38**:1008-1015.
- Dice LR: **Measures of the amount of ecological association between species.** *Ecology* 1945, **26**:297-302.
- Oliveira DC, de Lencastre H: **Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant *Staphylococcus aureus*.** *Antimicrob Agents Chemother* 2002, **46**:2155-2161.
- Boyle-Vavra S, Ereshefsky B, Wang CC, Daum RS: **Successful multi-resistant community-associated methicillin-resistant *Staphylococcus aureus* lineage from Taipei, Taiwan, that carries either the novel staphylococcal chromosome cassette mec (SCCmec) type V_T or SCCmec type IV.** *J Clin Microbiol* 2005, **43**:4719-4730.
- Hiramatsu K, Kihara H, Yokota T: **Analysis of borderline-resistant strains of methicillin-resistant *Staphylococcus aureus* using polymerase chain reaction.** *Microbiol Immunol* 1992, **36**:445-453.
- Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Vandenesch F, Etienne J: **Involvement of Panton-Valentine leukocidin-producing *Staphylococcus aureus* in primary skin infections and pneumonia.** *Clin Infect Dis* 1999, **29**:1128-1132.
- Almer LS, Shortridge VD, Niluis AM, Beyer JM, Soni NB, Bui MH, Stone GG, Flamm RK: **Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant *Staphylococcus aureus*.** *Diagn Microbiol Infect Dis* 2002, **43**:225-232.
- Shortridge VD, Flamm RK, Ramer N, Beyer J, Tanaka SK: **Novel mechanism of macrolide resistance in *Streptococcus pneumoniae*.** *Diagn Microbiol Infect Dis* 1996, **26**:73-78.
- Williams REO: **Healthy carriage of *Staphylococcus aureus*: its prevalence and importance.** *Bacteriol Rev* 1963, **27**:56-71.
- Salgado CD, Farr BM, Calfee DP: **Community-acquired methicillin-resistant *Staphylococcus aureus*: a meta-analysis of prevalence and risk factors.** *Clin Infect Dis* 2003, **36**:131-139.
- Shopsin B, Mathema B, Martinez J, Ha E, Campo ML, Fierman A, Krainski K, Kornblum J, Alcibes P, Waddington M, Riehman M, Kreiswirth BN: **Prevalence of methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* in the community.** *J Infect Dis* 2000, **182**:359-362.
- Sá-Leão R, Sanches IS, Couto I, Alves R, De Lencastre H: **Low prevalence of methicillin-resistant strains among *Staphylococcus***

- aureus** colonizing young and healthy members of the community in Portugal. *Microb Drug Resist* 2001, **7**:237-245.
25. Lu PL, Chin LC, Peng CF, Chiang YH, Chen TP, Ma L, Siu LK: **Risk factors and molecular analysis of community methicillin-resistant *Staphylococcus aureus* carriage.** *J Clin Microbiol* 2005, **43**:132-139.
 26. Alfaro C, Mascher-Denen M, Fergie J, Purcell K: **Prevalence of methicillin-resistant *Staphylococcus aureus* nasal carriage in patients admitted to Driscoll Children's Hospital.** *Pediatr Infect Dis J* 2006, **25**:459-461.
 27. Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC: **Community-acquired and clindamycin-susceptible methicillin-resistant *Staphylococcus aureus* in children.** *Pediatr Infect Dis J* 1999, **18**:993-1000.
 28. Fergie JE, Purcell K: **Community-acquired methicillin-resistant *Staphylococcus aureus* infections in South Texas children.** *Pediatr Infect Dis J* 2001, **20**:860-863.
 29. Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, Etienne J: **Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among *Staphylococci*.** *Antimicrob Agents Chemother* 1999, **43**:1062-1066.
 30. Schmitz FJ, Verhoef J, Fluit AC: **Prevalence of resistance to MLS antibiotics in 20 European hospitals participating in the European SENTRY surveillance programme. SENTRY Participants Group.** *J Antimicrob Chemother* 1999, **43**:783-792.
 31. Marshall SA, Wilke WW, Pfaller MA, Jones RN: ***Staphylococcus aureus* and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (*mecA*) characterization of oxacillin resistance in the SCOPE program.** *Diagn Microbiol Infect Dis* 1998, **30**:205-214.
 32. Ito T, Okuma K, Ma XX, Yuzawa H, Hiramatsu K: **Insights on antibiotic resistance of *Staphylococcus aureus* from its whole genome: genomic island SCC.** *Drug Resist Update* 2003, **6**:41-52.
 33. Leclercq R: **Mechanisms of resistance to macrolides and lincosamides: nature of resistance elements and their clinical implications.** *Clin Infect Dis* 2002, **34**:482-492.
 34. Deurenberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE: **The molecular evolution of methicillin-resistant *Staphylococcus aureus*.** *Clin Microbiol Infect* 2007, **13**:222-235.
 35. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, Lin F, Lin J, Carleton HA, Mongodin EF, Sensabaugh GF, Perdreau-Remington F: **Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant *Staphylococcus aureus*.** *Lancet* 2007, **367**:731-739.
 36. Tenover FC, McDougal LK, Goering RV, Killgore G, Projan SJ, Patel JB, Dunman PM: **Characterization of a strain of community-acquired methicillin-resistant *Staphylococcus aureus* widely disseminated in the United States.** *J Clin Microbiol* 2006, **44**:108-118.
 37. Liu YC, Huang WK, Huang TS, Kunin CM: **Extent of antibiotic use in Taiwan shown by antimicrobial activity in urine.** *Lancet* 1999, **354**:1360.
 38. Chang SC, Shiu MN, Chen TJ: **Antibiotic usage in primary care units in Taiwan after the institution of national insurance.** *Diagn Microbiol Infect Dis* 2001, **40**:137-143.
 39. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piémont Y, Brousse N, Floret D, Etienne J: **Association between *Staphylococcus aureus* strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients.** *Lancet* 2002, **359**:753-759.
 40. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Liassine N, Bes M, Greenland T, Reverdy ME, Etienne J: **Community-acquired methicillin-resistant *Staphylococcus aureus* carrying Panton-Valentine leukocidin genes: worldwide emergence.** *Emerg Infect Dis* 2003, **9**:978-984.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2334/7/51/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

